Hospitalized patients with suspected or confirmed infection are commonly treated with vancomycin (VN) in combination with either piperacillin-tazobactam (PT) or cefepime (CP). Although these regimens have similar effectiveness, recent observational evidence suggests they may differ in terms of the risk for acute kidney injury (AKI). Interpretation of existing evidence is complicated by the limitations of creatinine, the standard biomarker used to monitor kidney function, which has poor sensitivity and specificity for drug induced AKI. To address this important knowledge gap, the investigators propose to conduct a pragmatic, open-label, non-inferiority trial that will examine the comparative risk of AKI between these standard-of-care antibiotic combinations using sensitive and specific markers of drug-induced AKI. We hypothesize that the regimen of VN in combination with PT (VN+PT) is noninferior to the regimen of VN in combination with CP (VN+CP) in terms of AKI risk.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Pennsylvania

NCT06712641

/ Not yet recruitingPhase 4IIT

Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis

Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance.
In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.

Start Date01 Jun 2025

Sponsor / Collaborator

Akershus Universitetssykehus HF

[+1]

ChiCTR2500101528

/ SuspendedNot ApplicableIIT

Impact of Perioperative Prophylactic Piperacillin-Tazobactam on Postoperative Infectious Complications in High-Risk Patients Undergoing Pancreaticoduodenectomy

Start Date01 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Piperacillin Sodium/Tazobactam Sodium

100 Translational Medicine associated with Piperacillin Sodium/Tazobactam Sodium

100 Patents (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

5,104

Literatures (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Green synthesis of silver nanoparticles using Acroptilon repens aqueous extract and their antibacterial efficacy against multidrug-resistant Acinetobacter baumannii

Article

Author: Shahbazi, Shahla ; Shamsoddini, Seyed Mahdi ; Karizi, Shohreh Zare ; Davoudi, Mahdieh

BACKGROUND:

Acinetobacter baumannii is a critical pathogen associated with hospital-acquired infections, particularly in burn and intensive care unit (ICU) patients, and is notorious for its high level of antibiotic resistance. This study aims to evaluate the antibacterial potential of silver nanoparticles (AgNPs) synthesized using Acroptilon repens extract as a promising alternative treatment for combating multidrug-resistant A. baumannii.

METHODS AND RESULTS:

Twelve clinical isolates of A. baumannii were identified through biochemical testing. Antibiotic susceptibility testing using the Kirby-Bauer disk diffusion method revealed universal resistance to ceftazidime, amikacin, imipenem, gentamicin, ciprofloxacin, and piperacillin-tazobactam, while all isolates remained sensitive to colistin (p ≤ 0.05). AgNPs were synthesized using A. repens extract and characterized through transmission electron microscopy (TEM), scanning electron microscopy (SEM), particle size analysis (PSA), UV-Vis spectroscopy, X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FT-IR). TEM analysis showed that the AgNPs had a spherical morphology with an average particle size of approximately 30 nm, while SEM confirmed their spherical shape and size distribution, ranging from 10 to 130 nm, with a mean size of 38.89 nm. UV-Vis spectroscopy confirmed the successful formation of AgNPs, indicated by a distinct broad absorption peak between 400 and 480 nm. XRD analysis validated the crystalline nature of the nanoparticles, with characteristic peaks at 2θ values of 38.21°, 46.28°, 64.57°, and 77.49°, corresponding to the (111), (200), (220), and (311) planes of face-centered cubic (fcc) silver. Antibacterial activity was evaluated by determining the minimum inhibitory concentration (MIC), which ranged from 50 to 400 µg/mL. The highest inhibitory activity was observed at 400 µg/mL. Gene expression analysis using quantitative real-time PCR (qRT-PCR) demonstrated downregulation of the oprD and carO porin genes following AgNP treatment. However, these reductions were not statistically significant (p = 0.302 and p = 0.198, respectively).

CONCLUSIONS:

AgNPs synthesized from A. repens demonstrated strong antibacterial activity against multidrug-resistant A. baumannii. While downregulation of porin genes was observed, further investigation is required to elucidate the underlying mechanisms of action and assess their potential clinical applications. These findings support the potential of AgNPs as an alternative therapeutic strategy for addressing A. baumannii infections resistant to conventional antibiotics.

01 Jun 2025·JOURNAL OF HAZARDOUS MATERIALS

Metagenomic insights into the inhibitory effect of phytochemical supplementation on antibiotic resistance genes and virulence factors in the rumen of transition dairy cows

Article

Author: Zhao, Huiying ; Zhang, Ao ; Jiang, Linshu ; Wang, Ying ; Tan, Jian ; Zhao, Yuchao ; Li, Liuxue

Antimicrobial resistance (AMR) is a major global health concern, with the rumen microbiota of dairy cows serving as an important reservoir for antibiotic resistance genes (ARGs) and virulence factors (VFs). This study explores the impact of dietary phytochemical supplementation on the rumen resistome and virulome of transition dairy cows using metagenomic sequencing. Naringin supplementation reduced the abundance of ARGs by up to 9.0 % and VFs by up to 7.2 % during the transition period, as indicated by metagenomic analysis (P < 0.05). Clinically high-risk ARGs, including those conferring resistance to beta-lactams (mecA), tetracyclines (tetM, tetO), and aminoglycosides (rmtF), were notably downregulated (P < 0.05). Virulence factors associated with adherence, secretion systems, and toxins were also significantly decreased (P < 0.05). Naringin altered the microbial community structure, particularly reducing the abundance of Proteobacteria, a key phylum harboring ARGs and VFs. Despite inducing increased ARG-VF network complexity, naringin supplementation promoted a less pathogenic microbiome with reduced resistance potential. These findings demonstrate the potential of naringin as a natural dietary strategy to mitigate AMR by reducing the risk of ARG and VF dissemination into the environment, while supporting rumen microbiota stability in transition dairy cows.

01 Jun 2025·Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Evaluating the innovative potential of the global antibacterial pipeline

Review

Author: Theuretzbacher, Ursula

BACKGROUND:

Resistance burden varies widely among WHO regions, and the potential impact of new antibiotics differs in addressing the WHO's critical priority pathogens' resistance challenge.

OBJECTIVES:

To analyse the current global clinical pipeline in line with public and global health concerns and define innovation in antibacterial drug discovery.

SOURCES:

Monitoring clinical pipelines since 2006, integrating peer-reviewed MEDLINE publications on clinical development of new antibacterial agents, supplemented with disclosed data from developers.

CONTENT:

The current clinical pipeline is dominated by derivatives of established antibiotic classes, primarily β-lactamase inhibitor combinations in Phase 3 (six of ten which also include two beta-lactams without β-lactamase inhibitor). This pattern extends to Phase 1. Although incremental improvements in susceptibility rates among derivatives benefit patients in advanced health care systems within specific geographical regions, these concepts are not adequate for carbapenem-resistant strains of Enterobacterales (especially Klebsiella and Escherichia coli), Acinetobacter, and Pseudomonas. This limitation arises from the diverse distribution of resistance mechanisms across global regions. Innovation in this context refers to absence of cross-resistance because of class-specific resistance mechanisms. This can most likely be achieved by exploring new chemical classes and new targets/binding sites, and new mode of action. An initial glimpse of progress is evident as innovative agents progressed to Phase 1 clinical trials. However, an influx of more agents advancing to clinical development is essential given the inherent risks associated with novel chemistry and targets.

IMPLICATIONS:

The limited innovation in the global clinical pipeline inadequately serves public and global health interests. The complexities of antibacterial drug discovery, from scientific challenges to financial constraints, underscore the need for collective researcher efforts and public support to drive innovation for patients globally.

News (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

18 Dec 2024

·www.businesswire.com

Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board

BOSTON--( BUSINESS WIRE )--Valink Therapeutics, a biopharmaceutical company focused on discovering and developing innovative bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases, has appointed Martin D. Williams as Chair of its Board of Directors. The company also named its Scientific Advisory Board, which assembles experts in the discovery, development, manufacture and commercialization of ADCs and bispecific therapeutics. “ We are thrilled to welcome Martin, whose expertise in strategy, development and partnering, and track record of leading multiple U.S. biopharmaceutical companies, will be instrumental to the next stages of Valink. He brings deep experience advancing a wide range of therapeutics from early development through regulatory approval and commercialization and developing industry partnerships that move promising medicines closer to patients. Martin’s career journey, which began in the UK before his move to the U.S. over 30 years ago, mirrors Valink’s roots as a University of Oxford spinout based in the U.S., with a strong UK presence,” said Arne Scheu, DPhil, Co-founder and Chief Executive Officer of Valink. “ Furthermore, I am excited to announce our Scientific Advisory Board, which brings together a distinguished group of advisors who have been at the forefront of ADC and bispecific innovation and development.” Mr. Williams brings to Valink more than 35 years of experience in the global biopharmaceutical business, having closed more than $5 billion worth of corporate transactions, including numerous partnerships, M&A, and public and private financings. He recently served as Chief Executive Officer of Caraway Therapeutics, a venture-backed company developing therapeutics to modulate lysosomal function for neurodegenerative and rare diseases, through the company’s acquisition by Merck & Co. at the end of 2023. Previously, he was President and Chief Executive Officer of Tokai Pharmaceuticals, a clinical-stage oncology company; Chief Business Officer at Dicerna Pharmaceuticals, a leading RNAi company with programs in oncology; and Chief Business Officer and Senior Vice President for commercial and business development at Synta Pharmaceuticals, a clinical-stage public company focused on oncology and inflammation. Earlier in his career, he held various leadership positions and directed the development, commercialization and launch of several flagship brands for GSK, Hoffmann-La Roche and Lederle/Wyeth (now Pfizer), including GSK’s blockbusters Zantac® and Zofran®; Hoffmann La-Roche’s Xenical®; and Lederle/Wyeth’s global anti-infective portfolio, including Zosyn®/Tazocin®. He holds an MBA from Harvard Business School and an MS from the University of Manchester, UK. “ Valink has developed a compelling approach to realizing the unmet potential of ADCs to improve outcomes for patients with cancer and other diseases, which has been restricted by dose-limiting toxicities and the range of suitable targets. Their technology addresses a significant challenge to ADC innovation by enabling rapid and cost-effective generation and screening of bispecific ADCs, unlocking a vast range of target synergy and potentially bringing previously undruggable space within reach,” said Mr. Williams. “ I am excited to work closely with the Valink executive team and Board as the company builds on its discoveries and pursues its clinical aspirations.” Valink also announced the formation of its Scientific Advisory Board, initially consisting of: Sonia Quaratino, MD, PhD is Executive Vice President and Chief Medical Officer at Innate Pharma, a clinical-stage biotech utilizing monoclonal antibodies, multi-specific NK cell engagers and ADCs to develop immunotherapies for cancer. Her career spans over 25 years in basic research, clinical development and translational medicine across academia, biotech and global pharmaceuticals. She has held numerous leadership positions, including serving as CMO at Kymab (until its acquisition by Sanofi) and Georgiamune Inc, and was Professor of Immunology at the University of Southampton. Marc Damelin, PhD is Chief Scientific Officer at Alphina Therapeutics and an expert in oncology drug discovery and development. Previously he served as VP and Head of Biology at Mersana Therapeutics, a clinical-stage biotech developing ADCs to treat cancer. Prior to that he worked for a decade in ADC discovery and development in Pfizer's Oncology Research Unit. Robert Lutz, PhD , Chief Scientific Officer at leading ADC company Iksuda Therapeutics, is a recognized expert in ADC discovery and development. As VP of Translational R&D at ImmunoGen, he was responsible for bringing eight ADC product candidates into development and was the research lead for Kadcyla®, the first ADC to be approved for solid tumor indications. Antoine Awad , Principal Executive Officer of Synlogic, has extensive experience in CMC, bispecific drug development and partnerships. Prior to Synlogic, he held leadership positions at various biotechs, including Merrimack Pharmaceuticals, where he led CMC development, manufacturing and approval of ONIVYDE® for treatment of advanced pancreatic cancer and transitioned to Ipsen Bioscience to lead global commercial manufacturing of ONIVYDE®. Mihriban Tuna, PhD is Chief Executive Officer of Immutrin and Entrepreneur-in-Residence at Cambridge Innovation Capital, a leading UK-based venture company focused on deep tech and life sciences. She previously served as Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda) and SVP, Drug Discovery at F-star Therapeutics, and was an early employee at Domantis Ltd. (acquired by GSK). Alexey A. Lugovskoy, PhD is President and Chief Executive Officer of Diagonal Therapeutics, Entrepreneur-in-Residence at Atlas Ventures and Associate Editor of mAbs . He formerly served as Chief Operating Officer at Dragonfly, Chief Development Officer at Morphic, Vice President of Therapeutics at Merrimack Pharmaceuticals and Associate Director of Drug Discovery at Biogen. He joined Valink’s Board of Directors in 2023, and this additional appointment highlights a close collaboration between the Scientific Advisory Board, Board of Directors and leadership team. About Valink Therapeutics Valink Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases. Valink’s technology platform utilizes a modular assembly approach to rapidly generate bsADCs with therapeutic potential, testing drugs at unparalleled scale and speed to improve on the payload delivery and selectivity of conventional ADCs. The company is based in Boston, Massachusetts and has research and development operations in London, UK. For more information, visit the company’s website at www.valinktx.com or contact the company at connect@valinktx.com .

Executive ChangeADCAcquisitionDrug Approval

28 Jun 2024

·www.pharmaindustrial-india.com

Orchid Pharma and Cipla to Launch Cefepime-Enmetazobactam in India

Orchid Pharma has launched its new drug, Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. In a landmark collaboration, Orchid Pharma has partnered with Cipla to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in the fight against AMR, a growing global health issue, reinforcing India’s leadership in medical innovation. Orchid Pharma and Cipla are confident that this collaboration will set a new benchmark for addressing critical healthcare challenges through strategic partnerships and advanced research. The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India as quickly and efficiently as possible. Speaking on the launch, Manish Dhanuka, Managing Director Orchid Pharma said, "With increasing resistance to the current drugs most commonly used for treatment of these indications, e.g., Piperacillin-Tazobactam for cUTI – doctors were forced to start using Carbapenems – a reserve drug meant to be used when most other drugs don't work. Now, Orchid's Cefepime- Enmetazobactam will allow doctors to spare Carbapenems, prolonging their effective life by restricting their use." Umang Vohra, Managing Director & Global Chief Executive Officer, Cipla, said, “AMR is an urgent and serious healthcare challenge that needs global attention. With the rising incidence of potentially threatening infections, there is a strong need for novel anti-infectives in the effective treatment of MDR infections. This partnership enhances Cipla’s commitment to AMR stewardship and strengthens our efforts to combat infectious diseases and deliver advanced, innovative therapies to patients.” Both companies are committed to responsible antibiotic stewardship and will work closely with healthcare professionals to ensure the appropriate use of this new antibiotic combination. Educational initiatives and guidelines for prescribing will be developed to maximize the drug's benefits while minimizing the risk of further antimicrobial resistance.

Drug Approval

13 May 2024

·www.sciencedaily.com

Commonly used antibiotic brings more complications, death in the sickest patients

Treatment with the commonly used antibiotic piperacillin/tazobactam was associated with a 5 percent increase in 90-day mortality, more days on a ventilator, and more time with organ failure for patients with sepsis, finds a new study. In emergency rooms and intensive care units across the country, clinicians make split-second decisions about which antibiotics to give a patient when a life-threatening infection is suspected. A new U-M study reveals that these decisions may have unintended consequences for patient outcomes. Beginning in 2015, a 15-month national shortage of a commonly prescribed antibiotic, piperacillin/tazobactam, known by the brand name Zosyn, provided a unique opportunity to compare rates of death in hospitalized patients with sepsis who were administered two different types of antibiotics -- one that spares the gut microbiome and one that profoundly alters it. Piperacillin/tazobactam is a broad-spectrum antibiotic that is commonly administered for sepsis, a life-threatening complication from infection. In its absence, clinicians commonly instead use another antibiotic, cefepime, which has similar activity against common sepsis pathogens but, unlike piperacillin/tazobactam, has minimal effects on anaerobic gut bacteria. "We saw this Zosyn shortage as a one-of-a-kind opportunity to ask whether this antibiotic, which we know depletes the gut of anaerobic bacteria, makes a difference in terms of patient outcomes," said Robert Dickson, M.D. of the Department of Medicine's Division of Pulmonary & Critical Care Medicine and Deputy Director of the Weil Institute for Critical Care Research & Innovation. In health, the gut microbiome is largely populated by anaerobic bacteria that rarely cause disease. Prior work by the study team has revealed that even a single dose of piperacillin/tazobactam kills most of these anaerobic gut bacteria, which play important roles in the body's metabolism, immunity, and prevention of infections. Dickson, Rishi Chanderraj, M.D. of the Division of Infectious Disease, Michael Sjoding, M.D. of the Division of Pulmonary & Critical Care Medicine and their multidisciplinary team at U-M and the VA Ann Arbor used patient record data to look at outcomes in 7,569 patients. The team compared 4,523 patients who were treated were piperacillin/tazobactam with 3,046 patients who received cefepime. They found marked differences: treatment with piperacillin-tazobactam was associated with a 5 percent increase in 90-day mortality, more days on a ventilator, and more time with organ failure. "These are powerful antibiotics that are administered to patients every day in every hospital nationwide," said Chanderraj. "Clinicians use them because they are trying to treat every possible pathogen that might be causing their patients' illness. But our results suggest that their effects on the microbiome might also have important effects on patient outcomes." The study builds on previous work by the study team that suggested critically ill patients may do worse when given antibiotics that deplete the gut of anaerobes. They have also seen similar effects when studying animal models. "Our prior work suggested that there might be harm with piperacillin/tazobactam, but it was an observational study that had some limitations," said Sjoding, the study's senior author. "That's why the drug shortage was such an amazing opportunity. It created an almost perfect natural experiment that let us test the difference between these two drugs on patient outcomes in a very rigorous manner." A recent clinical trial pitted these two antibiotics against each other and compared side effects and mortality after two weeks. That trial did not find any differences in the short term -- a finding that the U-M team also observed in their analysis. "When we looked at two-week outcomes in our study, we didn't find differences either," said Chanderraj. "But the differences at three months were dramatic." Overall, the new findings suggest that treatment with piperacillin/tazobactam instead of cefepime may contribute to one additional death per every 20 septic patients treated. "A 5% mortality difference has enormous implications because sepsis is so common," said Dickson. "Every day, thousands of clinicians are deciding which of these drugs to use in septic patients." Physicians should give more thought about whether anti-anerobic antibiotics are warranted before prescribing them, added Chanderraj. "We need to think about antibiotics like chemotherapy. In the right context, treatment can be lifesaving, but in the wrong context, it can be quite harmful."

Clinical Result

100 Deals associated with Piperacillin Sodium/Tazobactam Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
-	Piperacillin Sodium/Tazobactam Sodium	J01CR05	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pelvic Infection	United States	Wyeth Pharmaceuticals LLC	26 May 2020
Staphylococcal Skin Infections	Japan	Taiho Pharmaceutical Co., Ltd.	18 May 2017
Ulcer	Japan	Taiho Pharmaceutical Co., Ltd.	18 May 2017
Neutropenia	Japan	Taiho Pharmaceutical Co., Ltd.	26 Jun 2015
Abdominal Abscess	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Cholangitis	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Cholecystitis	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Gynecological infection	Australia	Sandoz Pty Ltd.	10 Dec 2008
Lower Respiratory Tract Infections	Australia	Sandoz Pty Ltd.	10 Dec 2008
Sepsis	Australia	Sandoz Pty Ltd.	10 Dec 2008
Urinary Tract Infections	Australia	Sandoz Pty Ltd.	10 Dec 2008
Cystitis	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Hemorrhagic Septicemia	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Pyelonephritis	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Endometritis	United States	Baxter Healthcare Corp.	06 May 2003
Community Acquired Pneumonia	United States	Baxter Healthcare Corp.	24 Feb 1998
Abscess	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Appendicitis	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Cellulitis	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Diabetic Foot	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Febrile Neutropenia	Phase 3	United States	Wyeth AB	06 Sep 2002
Febrile Neutropenia	Phase 3	Canada	Wyeth AB	06 Sep 2002
Lymphoma	Phase 3	United States	Wyeth AB	06 Sep 2002
Lymphoma	Phase 3	Canada	Wyeth AB	06 Sep 2002
Hematologic Neoplasms	Phase 3	United States	Wyeth AB	04 Sep 2002
Hematologic Neoplasms	Phase 3	Canada	Wyeth AB	04 Sep 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05753735 (CTgov)	Phase 2	Pancreatic Fistula	3	Piperacillin/Tazobactam (Standard Perioperative Antibiotics)	zdtelyvsub(xkswspcqfg) = wlnqjwcibo hktacdatlo (pqioopepej, hshewrpotv - zsrvnqkdgc) View more	-	24 Sep 2024
				Piperacillin/Tazobactam+Amoxicillin/ Clavulanic acid (Extended Antibiotic Prophylaxis)	stuowrsygt = vaoebsdlov owzgtojsxc (ntuqowndki, fayksmbwsq - reeqtjekvo) View more
APAO2024	Not Applicable	-	-	Piperacillin-Tazobactam Eye Drops in Water for Injection (WFI)	ytgrdzlbjx(oelsfxqijm) = rfczznyefj ocubhotgmd (antjhknbbj ) View more	Positive	22 Feb 2024
				Piperacillin-Tazobactam Eye Drops in Carboxymethyl Cellulose (CMC)	ytgrdzlbjx(oelsfxqijm) = jecvhkmiqn ocubhotgmd (antjhknbbj ) View more
NCT03289351 (CTgov)	Phase 4	Postoperative infection \| Appendicitis	162	metronidazole+ceftriaxone (2-drug Therapy)	kdnhvxnkoc = zgwswwnmsy rfrgduapxl (xmtbjwvazi, qznhjbifzc - lqmctsgyud) View more	-	12 Jan 2024
				Piperacillin, Tazobactam Drug Combination (1-drug Therapy)	kdnhvxnkoc = icybyrgdbg rfrgduapxl (xmtbjwvazi, xqlpsvpdoz - uqfvljgjad) View more
NCT05102162 (CTgov)	Phase 4	Pneumonia	35	Meropenem+Piperacillin/Tazobactam+Cefepime (Continuous Antibiotic Dose Over 24 Hours Arm)	epzfhxzejy = uqxssqcdij rtboakmjpr (qprqlipkcy, ifxkpwrzre - lpoqpipntq) View more	-	12 Dec 2023
				Meropenem+Piperacillin/Tazobactam+Cefepime (Intermittent Antibiotic Dose Over 30 Minutes)	epzfhxzejy = cjhuvglxtz rtboakmjpr (qprqlipkcy, rjrcjcowlw - elrfekatqf) View more
NCT03269994 (Pubmed)	Phase 3	-	778	Piperacillin-Tazobactam	jlxflhcrww(wxeygllovb) = lminfsejju mvfmzfswni (lbqxxmcrge )	-	20 Apr 2023
				Cefoxitin	jlxflhcrww(wxeygllovb) = ybcmwaaxjo mvfmzfswni (lbqxxmcrge )
NCT01694069 (PIPE-CF, CTgov)	Phase 4	Cystic Fibrosis	6	Piperacillin-tazobactam combination product (Intermittent Infusion Piperacillin-tazobactam)	dzkflaydlr(znjdsmppzi) = zgcpowvipj mjxiaangzr (ltwcvpuzuq, nuqtzbwwpv - zwkmvulhmk) View more	-	01 Feb 2022
				Piperacillin-tazobactam combination product (Continuous Infusion Piperacillin-tazobactam)	dzkflaydlr(znjdsmppzi) = hmkcdjdlng mjxiaangzr (ltwcvpuzuq, brngfjxuzt - xohriywusx) View more
NCT02991937 (CTgov)	Phase 4	Appendicitis	39	Piperacillin/Tazobactam (Medical Therapy)	gpwjxxpdes(szggdkyfto) = hkuwqleiju upogsnlgjr (wvflbljabi, ngzbzxogxs - efouephrzn) View more	-	21 Jan 2022
				Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention)	gpwjxxpdes(szggdkyfto) = hgptsjorrz upogsnlgjr (wvflbljabi, sjwqsckwpz - uyrkmwpdxf) View more
NCT03019965 (CTgov)	Not Applicable	Sepsis	426	Meropenem+Imipenem+Piperacillin+Tazobactam (Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem)	aziorhtnui = vyhlgcrpez zwfdeeoygl (bfcipliocx, kfwexdzmrl - qtcfjfpfvh) View more	-	05 Aug 2021
				Meropenem+Imipenem+Piperacillin+Tazobactam (Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem)	aziorhtnui = sbrsjzehtd zwfdeeoygl (bfcipliocx, xcxnausczc - rghbpdxzyv) View more
EHA2021	Not Applicable	Hematopoietic stem cell transplantation	190	Aerobic antibiotics	ybsracwzhv(xdmxeepueo) = rvpgpdoiqp ktjpfpcpvl (mailhqizxz )	-	09 Jun 2021
ATS2021	Not Applicable	Critical Illness	-	Piperacillin-Tazobactam	hflkmdxsbu(lbdeouqrzb): adjusted odd ratio = 1.03 (95% CI, 0.83 - 1.27), P-Value = 0.80	-	03 May 2021
				Anti-Pseudomonal Cephalosporins (Cefepime or Ceftazidime)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Piperacillin Sodium/Tazobactam Sodium

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation